Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
Company: |
Mirum Pharmaceuticals |
|
|
|
|
Headquarters Address: |
950 Tower Lane |
|
|
Suite 1050 |
|
|
Foster City, CA 94404 |
|
|
|
|
Main Telephone: |
650-667-4085 |
|
|
|
|
Website: |
||
|
|
|
Ticker: |
MIRM(NASDAQ) |
|
|
|
|
Type of Organization: |
Public |
|
|
|
|
Industry: |
Biotechnology |
|
|
|
|
Key Executives: |
CFO: Ian Clements |
|
|
|
|
Investor Relations |
|
|
Contact: |
Ian Clements |
|
Email: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190926005500/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
